A
Arzu Onar-Thomas
Researcher at St. Jude Children's Research Hospital
Publications - 120
Citations - 4992
Arzu Onar-Thomas is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 26, co-authored 94 publications receiving 3544 citations. Previous affiliations of Arzu Onar-Thomas include Duke University.
Papers
More filters
Journal ArticleDOI
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
Gang Wu,Alexander K. Diaz,Alexander K. Diaz,Barbara S. Paugh,Sherri Rankin,Bensheng Ju,Yongjin Li,Xiaoyan Zhu,Chunxu Qu,Xiang Chen,Junyuan Zhang,John Easton,Michael N. Edmonson,Xiaotu Ma,Charles Lu,Panduka Nagahawatte,Erin Hedlund,Michael Rusch,Stanley Pounds,Tong Lin,Arzu Onar-Thomas,Robert Huether,Richard W. Kriwacki,Matthew Parker,Pankaj Gupta,Jared Becksfort,Lei Wei,Heather L. Mulder,Kristy Boggs,Bhavin Vadodaria,Donald Yergeau,Jake C. Russell,Kerri Ochoa,Robert S. Fulton,Lucinda Fulton,Chris Jones,Frederick A. Boop,Alberto Broniscer,Cynthia Wetmore,Amar Gajjar,Li Ding,Elaine R. Mardis,Richard K. Wilson,Michael R. Taylor,James R. Downing,David W. Ellison,Jinghui Zhang,Suzanne J. Baker,Suzanne J. Baker +48 more
TL;DR: In this article, the authors analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGG (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.
Journal ArticleDOI
Novel mutations target distinct subgroups of medulloblastoma
Giles W. Robinson,Matthew Parker,Tanya A. Kranenburg,Charles Lu,Charles Lu,Xiang Chen,Li Ding,Li Ding,Timothy N. Phoenix,Erin Hedlund,Lei Wei,Xiaoyan Zhu,Nader Chalhoub,Suzanne J. Baker,Robert Huether,Richard W. Kriwacki,Natasha Curley,Radhika Thiruvenkatam,Jianmin Wang,Gang Wu,Michael Rusch,Xin Hong,Xin Hong,Jared Becksfort,Pankaj Gupta,Jing Ma,John Easton,Bhavin Vadodaria,Arzu Onar-Thomas,Tong Lin,Shaoyi Li,Stanley Pounds,Steven W. Paugh,David Zhao,Daisuke Kawauchi,Martine F. Roussel,David Finkelstein,David W. Ellison,Ching C. Lau,Eric Bouffet,Tim Hassall,Tim Hassall,Sridharan Gururangan,Sridharan Gururangan,Richard J. Cohn,Richard J. Cohn,Robert S. Fulton,Robert S. Fulton,Lucinda L. Fulton,Lucinda L. Fulton,David J. Dooling,David J. Dooling,Kerri Ochoa,Kerri Ochoa,Amar Gajjar,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Jinghui Zhang,Richard J. Gilbertson +59 more
TL;DR: Modelling of mutations in mouse lower rhombic lip progenitors that generate WNT-subgroup tumours identified genes that maintain this cell lineage (DDX3X), as well as mutated genes that initiate (CDH1) or cooperate (PIK3CA) in tumorigenesis.
Journal ArticleDOI
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson,Brent A. Orr,Gang Wu,Sridharan Gururangan,Tong Lin,Ibrahim Qaddoumi,Roger J. Packer,Stewart Goldman,Michael D. Prados,Annick Desjardins,Murali Chintagumpala,Naoko Takebe,Sue C. Kaste,Michael Rusch,Sariah Allen,Arzu Onar-Thomas,Clinton F. Stewart,Maryam Fouladi,James M. Boyett,Richard J. Gilbertson,Tom Curran,David W. Ellison,Amar Gajjar +22 more
TL;DR: Molecular analyses support the hypothesis that SMO inhibitor activity depends on the genomic aberrations within the tumor and should be advanced in SHH-MB studies.
Journal ArticleDOI
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Jason Fangusaro,Arzu Onar-Thomas,Tina Young Poussaint,Shengjie Wu,Azra H. Ligon,Neal I. Lindeman,Anuradha Banerjee,Roger J. Packer,Lindsay Kilburn,Stewart Goldman,Ian F. Pollack,Ibrahim Qaddoumi,Regina I. Jakacki,Paul G. Fisher,Girish Dhall,Patricia Baxter,Susan G. Kreissman,Clinton F. Stewart,David T.W. Jones,Stefan M. Pfister,Gilbert Vezina,Jessica S Stern,Ashok Panigrahy,Zoltan Patay,Benita Tamrazi,Jeremy Jones,Sofia Haque,David S. Enterline,Soonmee Cha,Michael Fisher,Laurence Austin Doyle,Malcolm A. Smith,Ira J. Dunkel,Maryam Fouladi +33 more
TL;DR: Results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumsentinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.
Journal ArticleDOI
Processing Speed, Attention, and Working Memory After Treatment for Medulloblastoma: An International, Prospective, and Longitudinal Study
Shawna L. Palmer,Carol L. Armstrong,Arzu Onar-Thomas,Shengjie Wu,Dana Wallace,Melanie J. Bonner,Jane E. Schreiber,Michelle A. Swain,Lynn Chapieski,Donald J. Mabbott,Sarah Knight,Robyn Boyle,Amar Gajjar +12 more
TL;DR: Of the three key domains, PS was estimated to have the lowest scores at 5 years after diagnosis, which should guide researchers who are aiming to develop efficacious cognitive intervention and rehabilitation programs, thereby improving the quality of survivorship for the pediatric medulloblastoma population.